Selected research
Market Analysis & Forecast
Global Diabetic Retinopathy Screening Software Market Analysis and Forecast 2026-2032
Market perspective
The global Diabetic Retinopathy Screening Software market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Diabetic Retinopathy Screening Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Diabetic Retinopathy Screening Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Diabetic Retinopathy Screening Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Diabetic Retinopathy Screening Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Diabetic Retinopathy Screening Software include Retmarker, Retina Labs, Eyenuk, Inc., RetinaLyze, Intelligent Retinal Imaging Systems(IRIS), Retina AI, Optomed, RetinaRisk and InHealth Intelligence, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Diabetic Retinopathy Screening Software, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Diabetic Retinopathy Screening Software, also provides the revenue of main regions and countries. Of the upcoming market potential for Diabetic Retinopathy Screening Software, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Diabetic Retinopathy Screening Software revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Diabetic Retinopathy Screening Software market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Diabetic Retinopathy Screening Software revenue, projected growth trends, production technology, application and end-user industry.
Diabetic Retinopathy Screening Software Segment by Company
Retmarker
Retina Labs
Eyenuk, Inc.
RetinaLyze
Intelligent Retinal Imaging Systems(IRIS)
Retina AI
Optomed
RetinaRisk
InHealth Intelligence
CSIRO
NEC Care
Diabetic Retinopathy Screening Software Segment by Type
Cloud Based
On-Premise
Diabetic Retinopathy Screening Software Segment by Application
Hospital Eye Diagnosis
Personal Screening
Medical Research
Diabetic Retinopathy Screening Software Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Retinopathy Screening Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diabetic Retinopathy Screening Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Retinopathy Screening Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Diabetic Retinopathy Screening Software in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Diabetic Retinopathy Screening Software company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Diabetic Retinopathy Screening Software revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cloud Based
- On-Premise
Applications
- Hospital Eye Diagnosis
- Personal Screening
- Medical Research
Companies covered
- Retmarker
- Retina Labs
- Eyenuk, Inc.
- RetinaLyze
- Intelligent Retinal Imaging Systems(IRIS)
- Retina AI
- Optomed
- RetinaRisk
- InHealth Intelligence
- CSIRO
- NEC Care
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Diabetic Retinopathy Screening Software Market by Type
- 1.2.1 Global Diabetic Retinopathy Screening Software Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Cloud Based
- 1.2.3 On-Premise
- 1.3 Diabetic Retinopathy Screening Software Market by Application
- 1.3.1 Global Diabetic Retinopathy Screening Software Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Hospital Eye Diagnosis
- 1.3.3 Personal Screening
- 1.3.4 Medical Research
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Diabetic Retinopathy Screening Software Market Dynamics
- 2.1 Diabetic Retinopathy Screening Software Industry Trends
- 2.2 Diabetic Retinopathy Screening Software Industry Drivers
- 2.3 Diabetic Retinopathy Screening Software Industry Opportunities and Challenges
- 2.4 Diabetic Retinopathy Screening Software Industry Restraints
3 Global Growth Perspective
- 3.1 Global Diabetic Retinopathy Screening Software Market Perspective (2021-2032)
- 3.2 Global Diabetic Retinopathy Screening Software Growth Trends by Region
- 3.2.1 Global Diabetic Retinopathy Screening Software Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Diabetic Retinopathy Screening Software Market Size by Region (2021-2026)
- 3.2.3 Global Diabetic Retinopathy Screening Software Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Diabetic Retinopathy Screening Software Revenue by Players
- 4.1.1 Global Diabetic Retinopathy Screening Software Revenue by Players (2021-2026)
- 4.1.2 Global Diabetic Retinopathy Screening Software Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Diabetic Retinopathy Screening Software Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Diabetic Retinopathy Screening Software Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Diabetic Retinopathy Screening Software Key Players Headquarters & Area Served
- 4.4 Global Diabetic Retinopathy Screening Software Players, Product Type & Application
- 4.5 Global Diabetic Retinopathy Screening Software Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Diabetic Retinopathy Screening Software Market CR5 and HHI
- 4.6.3 2025 Diabetic Retinopathy Screening Software Tier 1, Tier 2, and Tier 3
5 Diabetic Retinopathy Screening Software Market Size by Type
- 5.1 Global Diabetic Retinopathy Screening Software Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Diabetic Retinopathy Screening Software Revenue by Type (2021-2032)
- 5.3 Global Diabetic Retinopathy Screening Software Revenue Market Share by Type (2021-2032)
6 Diabetic Retinopathy Screening Software Market Size by Application
- 6.1 Global Diabetic Retinopathy Screening Software Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Diabetic Retinopathy Screening Software Revenue by Application (2021-2032)
- 6.3 Global Diabetic Retinopathy Screening Software Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Retmarker
- 7.1.1 Retmarker Company Information
- 7.1.2 Retmarker Business Overview
- 7.1.3 Retmarker Diabetic Retinopathy Screening Software Revenue and Gross Margin (2021-2026)
- 7.1.4 Retmarker Diabetic Retinopathy Screening Software Product Portfolio
- 7.1.5 Retmarker Recent Developments
- 7.2 Retina Labs
- 7.2.1 Retina Labs Company Information
- 7.2.2 Retina Labs Business Overview
- 7.2.3 Retina Labs Diabetic Retinopathy Screening Software Revenue and Gross Margin (2021-2026)
- 7.2.4 Retina Labs Diabetic Retinopathy Screening Software Product Portfolio
- 7.2.5 Retina Labs Recent Developments
- 7.3 Eyenuk, Inc.
- 7.3.1 Eyenuk, Inc. Company Information
- 7.3.2 Eyenuk, Inc. Business Overview
- 7.3.3 Eyenuk, Inc. Diabetic Retinopathy Screening Software Revenue and Gross Margin (2021-2026)
- 7.3.4 Eyenuk, Inc. Diabetic Retinopathy Screening Software Product Portfolio
- 7.3.5 Eyenuk, Inc. Recent Developments
- 7.4 RetinaLyze
- 7.4.1 RetinaLyze Company Information
- 7.4.2 RetinaLyze Business Overview
- 7.4.3 RetinaLyze Diabetic Retinopathy Screening Software Revenue and Gross Margin (2021-2026)
- 7.4.4 RetinaLyze Diabetic Retinopathy Screening Software Product Portfolio
- 7.4.5 RetinaLyze Recent Developments
- 7.5 Intelligent Retinal Imaging Systems(IRIS)
- 7.5.1 Intelligent Retinal Imaging Systems(IRIS) Company Information
- 7.5.2 Intelligent Retinal Imaging Systems(IRIS) Business Overview
- 7.5.3 Intelligent Retinal Imaging Systems(IRIS) Diabetic Retinopathy Screening Software Revenue and Gross Margin (2021-2026)
- 7.5.4 Intelligent Retinal Imaging Systems(IRIS) Diabetic Retinopathy Screening Software Product Portfolio
- 7.5.5 Intelligent Retinal Imaging Systems(IRIS) Recent Developments
- 7.6 Retina AI
- 7.6.1 Retina AI Company Information
- 7.6.2 Retina AI Business Overview
- 7.6.3 Retina AI Diabetic Retinopathy Screening Software Revenue and Gross Margin (2021-2026)
- 7.6.4 Retina AI Diabetic Retinopathy Screening Software Product Portfolio
- 7.6.5 Retina AI Recent Developments
- 7.7 Optomed
- 7.7.1 Optomed Company Information
- 7.7.2 Optomed Business Overview
- 7.7.3 Optomed Diabetic Retinopathy Screening Software Revenue and Gross Margin (2021-2026)
- 7.7.4 Optomed Diabetic Retinopathy Screening Software Product Portfolio
- 7.7.5 Optomed Recent Developments
- 7.8 RetinaRisk
- 7.8.1 RetinaRisk Company Information
- 7.8.2 RetinaRisk Business Overview
- 7.8.3 RetinaRisk Diabetic Retinopathy Screening Software Revenue and Gross Margin (2021-2026)
- 7.8.4 RetinaRisk Diabetic Retinopathy Screening Software Product Portfolio
- 7.8.5 RetinaRisk Recent Developments
- 7.9 InHealth Intelligence
- 7.9.1 InHealth Intelligence Company Information
- 7.9.2 InHealth Intelligence Business Overview
- 7.9.3 InHealth Intelligence Diabetic Retinopathy Screening Software Revenue and Gross Margin (2021-2026)
- 7.9.4 InHealth Intelligence Diabetic Retinopathy Screening Software Product Portfolio
- 7.9.5 InHealth Intelligence Recent Developments
- 7.10 CSIRO
- 7.10.1 CSIRO Company Information
- 7.10.2 CSIRO Business Overview
- 7.10.3 CSIRO Diabetic Retinopathy Screening Software Revenue and Gross Margin (2021-2026)
- 7.10.4 CSIRO Diabetic Retinopathy Screening Software Product Portfolio
- 7.10.5 CSIRO Recent Developments
- 7.11 NEC Care
- 7.11.1 NEC Care Company Information
- 7.11.2 NEC Care Business Overview
- 7.11.3 NEC Care Diabetic Retinopathy Screening Software Revenue and Gross Margin (2021-2026)
- 7.11.4 NEC Care Diabetic Retinopathy Screening Software Product Portfolio
- 7.11.5 NEC Care Recent Developments
8 North America
- 8.1 North America Diabetic Retinopathy Screening Software Revenue (2021-2032)
- 8.2 North America Diabetic Retinopathy Screening Software Revenue by Type (2021-2032)
- 8.2.1 North America Diabetic Retinopathy Screening Software Revenue by Type (2021-2026)
- 8.2.2 North America Diabetic Retinopathy Screening Software Revenue by Type (2027-2032)
- 8.3 North America Diabetic Retinopathy Screening Software Revenue Share by Type (2021-2032)
- 8.4 North America Diabetic Retinopathy Screening Software Revenue by Application (2021-2032)
- 8.4.1 North America Diabetic Retinopathy Screening Software Revenue by Application (2021-2026)
- 8.4.2 North America Diabetic Retinopathy Screening Software Revenue by Application (2027-2032)
- 8.5 North America Diabetic Retinopathy Screening Software Revenue Share by Application (2021-2032)
- 8.6 North America Diabetic Retinopathy Screening Software Revenue by Country
- 8.6.1 North America Diabetic Retinopathy Screening Software Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Diabetic Retinopathy Screening Software Revenue by Country (2021-2026)
- 8.6.3 North America Diabetic Retinopathy Screening Software Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Diabetic Retinopathy Screening Software Revenue (2021-2032)
- 9.2 Europe Diabetic Retinopathy Screening Software Revenue by Type (2021-2032)
- 9.2.1 Europe Diabetic Retinopathy Screening Software Revenue by Type (2021-2026)
- 9.2.2 Europe Diabetic Retinopathy Screening Software Revenue by Type (2027-2032)
- 9.3 Europe Diabetic Retinopathy Screening Software Revenue Share by Type (2021-2032)
- 9.4 Europe Diabetic Retinopathy Screening Software Revenue by Application (2021-2032)
- 9.4.1 Europe Diabetic Retinopathy Screening Software Revenue by Application (2021-2026)
- 9.4.2 Europe Diabetic Retinopathy Screening Software Revenue by Application (2027-2032)
- 9.5 Europe Diabetic Retinopathy Screening Software Revenue Share by Application (2021-2032)
- 9.6 Europe Diabetic Retinopathy Screening Software Revenue by Country
- 9.6.1 Europe Diabetic Retinopathy Screening Software Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Diabetic Retinopathy Screening Software Revenue by Country (2021-2026)
- 9.6.3 Europe Diabetic Retinopathy Screening Software Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Diabetic Retinopathy Screening Software Revenue (2021-2032)
- 10.2 China Diabetic Retinopathy Screening Software Revenue by Type (2021-2032)
- 10.2.1 China Diabetic Retinopathy Screening Software Revenue by Type (2021-2026)
- 10.2.2 China Diabetic Retinopathy Screening Software Revenue by Type (2027-2032)
- 10.3 China Diabetic Retinopathy Screening Software Revenue Share by Type (2021-2032)
- 10.4 China Diabetic Retinopathy Screening Software Revenue by Application (2021-2032)
- 10.4.1 China Diabetic Retinopathy Screening Software Revenue by Application (2021-2026)
- 10.4.2 China Diabetic Retinopathy Screening Software Revenue by Application (2027-2032)
- 10.5 China Diabetic Retinopathy Screening Software Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Diabetic Retinopathy Screening Software Revenue (2021-2032)
- 11.2 Asia Diabetic Retinopathy Screening Software Revenue by Type (2021-2032)
- 11.2.1 Asia Diabetic Retinopathy Screening Software Revenue by Type (2021-2026)
- 11.2.2 Asia Diabetic Retinopathy Screening Software Revenue by Type (2027-2032)
- 11.3 Asia Diabetic Retinopathy Screening Software Revenue Share by Type (2021-2032)
- 11.4 Asia Diabetic Retinopathy Screening Software Revenue by Application (2021-2032)
- 11.4.1 Asia Diabetic Retinopathy Screening Software Revenue by Application (2021-2026)
- 11.4.2 Asia Diabetic Retinopathy Screening Software Revenue by Application (2027-2032)
- 11.5 Asia Diabetic Retinopathy Screening Software Revenue Share by Application (2021-2032)
- 11.6 Asia Diabetic Retinopathy Screening Software Revenue by Country
- 11.6.1 Asia Diabetic Retinopathy Screening Software Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Diabetic Retinopathy Screening Software Revenue by Country (2021-2026)
- 11.6.3 Asia Diabetic Retinopathy Screening Software Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Diabetic Retinopathy Screening Software Revenue (2021-2032)
- 12.2 SAMEA Diabetic Retinopathy Screening Software Revenue by Type (2021-2032)
- 12.2.1 SAMEA Diabetic Retinopathy Screening Software Revenue by Type (2021-2026)
- 12.2.2 SAMEA Diabetic Retinopathy Screening Software Revenue by Type (2027-2032)
- 12.3 SAMEA Diabetic Retinopathy Screening Software Revenue Share by Type (2021-2032)
- 12.4 SAMEA Diabetic Retinopathy Screening Software Revenue by Application (2021-2032)
- 12.4.1 SAMEA Diabetic Retinopathy Screening Software Revenue by Application (2021-2026)
- 12.4.2 SAMEA Diabetic Retinopathy Screening Software Revenue by Application (2027-2032)
- 12.5 SAMEA Diabetic Retinopathy Screening Software Revenue Share by Application (2021-2032)
- 12.6 SAMEA Diabetic Retinopathy Screening Software Revenue by Country
- 12.6.1 SAMEA Diabetic Retinopathy Screening Software Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Diabetic Retinopathy Screening Software Revenue by Country (2021-2026)
- 12.6.3 SAMEA Diabetic Retinopathy Screening Software Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst